Novavax COVID-19 vaccine, recently cleared by U.S. regulators, was tested at UW

The Seattle Times

A protein-based COVID-19 vaccine that went through clinical trials at the UW Medicine Virology Research Clinic could soon be available in the U.S. The Food and Drug Administration this week authorized Novavax’s vaccine for emergency use in adults 18 and older. A green light from the Centers for Disease Control and Prevention is needed before Americans can get the two-dose vaccination.

Dr. Scott McClelland, Professor of Medicine, of Global Health, and of Epidemiology at UW, is quoted.

UW Medicine starts Novavax COVID-19 vaccine clinical trial (includes Scott McClelland)

Volunteer enrollment begins for Phase III clinical trial that will determine the efficacy of Novavax vaccine candidate.

UW Medicine investigators are starting volunteer enrollment for an investigational COVID-19 vaccine clinical trial. The Phase III study will examine whether the Novavax vaccine candidate can protect against SARS-CoV-2, the coronavirus responsible for COVID-19.

PBS NewsHour: Uncovering the Female Body's Secret Protection against HIV

By Heather Boerner

CAPE TOWN, South Africa — From where Linda-Gail Bekker sits as director of the Desmond Tutu HIV Centre in Cape Town, science has been losing ground against HIV for years, especially when it comes to young women. After all, in some parts of the country, girls who are 15 today have an 80 percent chance of acquiring HIV in their lifetimes.

“We’re really in the trenches here,” she said. “We have to bring all the technology, tools—you know, innovations—we can find to start turning that war around.”